Serotiny
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Serotiny - overview
Established
2014
Location
San Francisco, CA, US
Primary Industry
Biotechnology
About
Based in California, US, and co-founded by Colin Farlow (CEO) and Justin Farlow (CTO)in 2014, Serotiny operates as a biotechnology company specializing in molecular science, genetics & gene therapy. The firm has received investments from investors ND Capital and 8VC GP II. The company specializes in inventing genes that encode therapeutic multi-domain proteins, with the goal of improving therapeutic properties and addressing complex disease contexts. By combining software, DNA synthesis, and sequencing, Serotiny employs next-generation engineering techniques to develop bespoke genes that encode the multi-domain proteins essential for cell and gene therapies.
The company’s primary product, Therapeutic Multi-Domain Proteins (tMDPs), serves as the foundation for curative CAR- and CRISPR-based therapies where tMDPs are delivered as genetic material and expressed directly within the patient's cells, providing new functionalities to the targeted cells and yielding distinct therapeutic benefits based on the specific cellular context.
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy
Website
www.serotiny.com
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.